Robert Earle, MD
Psychiatry · Houston, TXNPI 1750506986
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 27.8% of the total.
Across 158 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$803
- Otsuka America Pharmaceutical, Inc.$409
- Lundbeck LLC$280
- Axsome Therapeutics, Inc.$225
- Neurocrine Biosciences, Inc.$199
- Takeda Pharmaceuticals U.S.A., Inc.$196
- plus $781 from 14 others
Across 224 payments — averaging $4698.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$557K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$266K
- Neurocrine Biosciences, Inc.$87K
- Axsome Therapeutics, Inc.$77K
- Janssen Research & Development, LLC$51K
- Novartis$15K
What the payments were for
- Food & beverage$2,892100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $803 |
| Otsuka America Pharmaceutical, Inc. | 20 | $409 |
| Lundbeck LLC | 12 | $280 |
| Axsome Therapeutics, Inc. | 11 | $225 |
| Neurocrine Biosciences, Inc. | 8 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $196 |
| Vanda Pharmaceuticals Inc. | 4 | $119 |
| Teva Pharmaceuticals USA, Inc. | 4 | $95 |
| E.r. Squibb & Sons, L.L.C. | 3 | $95 |
| Shire North American Group Inc | 4 | $74 |
| Sunovion Pharmaceuticals Inc. | 4 | $73 |
| Johnson & Johnson | 4 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $61 |
| Avanir Pharmaceuticals, Inc. | 4 | $57 |
| OWP Pharmaceuticals, Inc. | 3 | $44 |
| Biogen | 1 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Alkermes, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Merck | 1 | $16 |
How this compares
$2,893 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 15 | $47,080 |
| VraylarCariprazine Hcl | 15 | $21,072 |
| TrintellixVortioxetine Hydrobromide | 14 | $8,080 |
| BelsomraSuvorexant | 15 | $6,371 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 258 | $5,585 |
| Duloxetine Hcl | 266 | $5,047 |
| Aripiprazole | 152 | $4,083 |
| Lurasidone Hcl | 19 | $3,925 |
| Bupropion XlBupropion Hcl | 158 | $3,597 |
| Bupropion Hcl SrBupropion Hcl | 154 | $3,244 |
| Quetiapine Fumarate | 233 | $2,693 |
| Clonazepam | 494 | $2,297 |
| Ziprasidone Hcl | 28 | $2,264 |
| Trazodone Hcl | 329 | $2,093 |
| Sertraline Hcl | 274 | $2,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Fanapt | $119 | $47,08015 claims |
| AbbVieVraylar | $803 | $21,07215 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $196 | $8,08014 claims |
| MerckBelsomra | $16 | $6,37115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.